Jubilant Pharmova Analyst Meet Update: Near Term Growth Prospects Strained: Nirmal Bang

Generics medicines manufactured by Jubilant Pharmova Ltd. (Source: Company website). 

Jubilant Pharmova Analyst Meet Update: Near Term Growth Prospects Strained: Nirmal Bang

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Jubilant Pharmova Ltd. had organized an analyst day to detail its business plan for all the segments it operates in - contract development and manufacturing, radiopharma, allergy immunotherapy, drug discovery, contract research, active pharmaceutical ingredient and solid dosage formulations.

The company discussed about growth opportunities in each of these verticals and how it intends to invest to capture the same.

The message is clear from the management that CDMO, contract research and drug discovery segment is witnessing tailwinds and the company is investing in this segment to capitalise on the same.

For other segments, it is investing on long-term initiatives, which should take time to reflect in its financials.

Click on the attachment to read the full report:

Nirmal Bang Jubilant Pharmova -Analyst Meet Update-22 June 2021.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.